In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.

@article{Wildfeuer1998InVE,
  title={In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.},
  author={Alexander Wildfeuer and Hans Peter Seidl and I Paule and A Haberreiter},
  journal={Mycoses},
  year={1998},
  volume={41 7-8},
  pages={309-19}
}
The in vitro activity of voriconazole (UK-109, 496), a new antifungal triazole derivative, against 650 clinical isolates of yeasts, moulds and dermatophytes was compared with that of itraconazole, ketoconazole, amphotericin B and griseofulvin. The geometric means of the minimum inhibitory concentrations (MICs) of voriconazole were 0.05 microgram ml-1 against yeasts (n = 187), 0.58 microgram ml-1 against moulds (n = 260) and 0.08 microgram ml-1 against dermatophytes (n = 203). The overall… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Antifungal AgentsTherapeutic class ofKetoconazole
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Antifungal AgentsTherapeutic class ofItraconazole
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Antifungal AgentsTherapeutic class ofvoriconazole
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
AzolesChemical structure ofKetoconazole
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
AzolesChemical structure ofItraconazole
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
AzolesChemical structure ofvoriconazole
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The geometric means of the minimum inhibitory concentrations ( MICs ) of voriconazole were 0.05 microgram ml-1 against yeasts ( n = 187 ) , 0.58 microgram ml-1 against moulds ( n = 260 ) and 0.08 microgram ml-1 against dermatophytes ( n = 203 ) .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The geometric means of the minimum inhibitory concentrations ( MICs ) of voriconazole were 0.05 microgram ml-1 against yeasts ( n = 187 ) , 0.58 microgram ml-1 against moulds ( n = 260 ) and 0.08 microgram ml-1 against dermatophytes ( n = 203 ) .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
In vitro evaluation of voriconazole against clinical isolates of yeasts , moulds and dermatophytes in comparison with itraconazole , ketoconazole , amphotericin B and griseofulvin .
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The overall activity of voriconazole against yeasts and moulds was good , being similar to that of itraconazole , ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus ( mean MIC 0.23 microgram ml-1 ) and other Aspergillus species and showed noteworthy activity ( mean MICs 0.08 - 0.78 microgram ml-1 ) against emerging and less common clinical isolates of opportunistic moulds , such as Alternaria spp . ,
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
Voriconazole and the other two azoles , itraconazole and ketoconazole , were more active than griseofulvin in vitro against most dermatophytes tested .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
The in vitro activity of voriconazole ( UK-109 , 496 ) , a new antifungal triazole derivative , against 650 clinical isolates of yeasts , moulds and dermatophytes was compared with that of itraconazole , ketoconazole , amphotericin B and griseofulvin .
All Topics